Skip to main content

Advertisement

SpringerLink
Log in

African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

Racial disparity of breast cancer in each subtype and substage is not clear.

Methods

We reviewed 156,938 patients with breast cancer from 2010 to 2012 from the National Cancer Institute Surveillance, Epidemiology, and End Results database. Breast cancer was subtyped by hormone receptor (HR) and human epidermal growth factor 2 (HER2) status as HR+/HER2−, HR+/HER2+, HR−/HER2+, and HR−/HER2−.

Results

African American (AA) patients had worse overall survival (OS) and breast cancer cause-specific survival (BCSS) in HR+/HER2− stages III and IV breast cancer and HR−/HER2+ stage IV cancer; they had worse OS but not BCSS in HR+ /HER2− stage II cancer and HR−/HER2− stage II cancer.

Conclusion

AA patients with breast cancer had worse survival in certain subtype and stage, especially in ER+ breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Whitman S, Orsi J, Hurlbert M (2012) The racial disparity in breast cancer mortality in the 25 largest cities in the United States. Cancer Epidemiol 36:e147–e151

    Article  PubMed  Google Scholar 

  2. Newman LA, Griffith KA, Jatoi I et al (2006) Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24:1342–1349

    Article  PubMed  Google Scholar 

  3. O’Brien KM, Cole SR, Tse CK et al (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16:6100–6110

    Article  PubMed  PubMed Central  Google Scholar 

  4. Menashe I, Anderson WF, Jatoi I et al (2009) Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst 101:993–1000

    Article  PubMed  PubMed Central  Google Scholar 

  5. Schinkel JK, Zahm SH, Jatoi I et al (2014) Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data. Cancer Causes Control 25:959–968

    Article  PubMed  Google Scholar 

  6. Adams SA, Butler WM, Fulton J et al (2012) Racial disparities in breast cancer mortality in a multiethnic cohort in the Southeast. Cancer 118:2693–2699

    Article  PubMed  Google Scholar 

  7. Warner ET, Tamimi RM, Hughes ME et al (2012) Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Res Treat 136:813–821

    Article  PubMed  PubMed Central  Google Scholar 

  8. Warner ET, Tamimi RM, Hughes ME et al (2015) Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol 33:2254–2261

    Article  PubMed  PubMed Central  Google Scholar 

  9. Iqbal J, Ginsburg O, Rochon PA et al (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313:165–173

    Article  CAS  PubMed  Google Scholar 

  10. Mortel M, Rauscher GH, Murphy AM et al (2015) Racial and ethnic disparity in symptomatic breast cancer awareness despite a recent screen: the role of tumor biology and mammography facility characteristics. Cancer Epidemiol Biomark Prev 24:1599–1606

    Article  Google Scholar 

  11. Sparano JA, Wang M, Zhao F et al (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104:406–414

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Roseland ME, Pressler ME, Lamerato LE et al (2015) Racial differences in breast cancer survival in a large urban integrated health system. Cancer 121:3668–3675

    Article  CAS  PubMed  Google Scholar 

  13. Nurgalieva ZZ, Franzini L, Morgan R et al (2013) Surveillance mammography use after treatment of primary breast cancer and racial disparities in survival. Med Oncol 30:691

    Article  CAS  PubMed  Google Scholar 

  14. Dave B, Gonzalez DD, Liu ZB et al (2017) Role of RPL39 in metaplastic breast cancer. J Natl Cancer Inst 109

  15. Krishnamurti U, Wetherilt CS, Yang J et al (2017) Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. Hum Pathol 64:7–12

    Article  CAS  PubMed  Google Scholar 

  16. Li X, Oprea-Ilies GM, Krishnamurti U (2017) New developments in breast cancer and their impact on daily practice in pathology. Arch Pathol Lab Med 141:490–498

    Article  PubMed  Google Scholar 

  17. Li X, Wei B, Sonmez C et al (2017) High tumor budding count is associated with adverse clinicopathologic features and poor prognosis in breast carcinoma. Hum Pathol

  18. Li X, Wetherilt CS, Krishnamurti U et al (2016) Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer. Am J Clin Pathol 146:496–502

    Article  PubMed  Google Scholar 

  19. Li X, Yang J, Krishnamurti U et al (2017) Hormone receptor-positive breast cancer has a worse prognosis in male than in female patients. Clin Breast Cancer 17:356–366

    Article  CAS  PubMed  Google Scholar 

  20. Li X, Yang J, Peng L et al (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161:279–287

    Article  PubMed  Google Scholar 

  21. Li XB, Krishnamurti U, Bhattarai S et al (2016) Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol 145:871–878

    Article  PubMed  Google Scholar 

  22. Ogden A, Garlapati C, Li XB et al (2017) Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer. Sci Rep 7:42289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Pannu V, Mittal K, Cantuaria G et al (2015) Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers. Oncotarget 6:10487–10497

    Article  PubMed  PubMed Central  Google Scholar 

  24. Wright N, Rida P, Krishnamurti U et al (2017) Targeted drugs and diagnostic assays: companions in the race to combat ethnic disparity. Front Biosci (Landmark Ed) 22:193–211

    Article  Google Scholar 

  25. Wright N, Xia J, Cantuaria G et al (2017) Distinctions in breast tumor recurrence patterns post-therapy among racially distinct populations. PLoS ONE 12:e0170095

    Article  PubMed  PubMed Central  Google Scholar 

  26. Zelnak AB, Nikolinakos P, Srinivasiah J et al (2015) High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy. Clin Breast Cancer 15:31–36

    Article  CAS  PubMed  Google Scholar 

  27. Lund MJ, Trivers KF, Porter PL et al (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357–370

    Article  PubMed  Google Scholar 

  28. Dawood S, Broglio K, Kau SW et al (2009) Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27:220–226

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Chu KC, Lamar CA, Freeman HP (2003) Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer 97:2853–2860

    Article  PubMed  Google Scholar 

  30. Ma H, Lu Y, Malone KE et al (2013) Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC Cancer 13:1–11

    Article  Google Scholar 

  31. Gleason MX, Mdzinarishvili T, Sherman S (2012) Breast cancer incidence in black and white women stratified by estrogen and progesterone receptor statuses. PLoS ONE 7:e49359

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Wright JL, Reis IM, Zhao W et al (2012) Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy. Breast 21:276–283

    Article  CAS  PubMed  Google Scholar 

  33. Vaz-Luis I, Lin NU, Keating NL et al (2015) Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat 151:697–707

    Article  PubMed  Google Scholar 

  34. Tichy JR, Deal AM, Anders CK et al (2015) Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Res Treat 150:667–674

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. EBCTCG (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:1341–1352

    Article  Google Scholar 

  36. EBCTCG (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784

    Article  Google Scholar 

  37. Fisher B, Jeong J-H, Bryant J et al (2004) Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National surgical adjuvant breast and bowel project randomised clinical trials. Lancet 364:858–868

    Article  CAS  PubMed  Google Scholar 

  38. Friese CR, Pini TM, Li Y et al (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138:931–939

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Neugut AI, Subar M, Wilde ET et al (2011) Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534–2542

    Article  PubMed  PubMed Central  Google Scholar 

  40. Roberts MC, Wheeler SB, Reeder-Hayes K (2015) Racial/ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review. Am J of Public Health 105:e4–e15

    Article  Google Scholar 

  41. Ma H, Lu Y, Marchbanks PA et al (2013) Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. Breast Cancer Res 15:1–12

    Article  CAS  Google Scholar 

  42. Reding KW, Chen C, Lowe K et al (2012) Estrogen-related genes and their contribution to racial differences in breast cancer risk. Cancer Causes Control 23:671–681

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The research reported in this paper for publication was supported in part by the NIH/NCI under Award No. R01HL113548 (LP).

Author information

Authors and Affiliations

  1. Department of Surgery, Emory University, Atlanta, GA, USA

    Cletus A. Arciero

  2. Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA

    Jing Yang, Limin Peng & Kevin C. Ward

  3. Department of Medicine, University of Wisconsin, Madison, WI, USA

    Ruth O’Regan

  4. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Aysegul A. Sahin

  5. Department of Pathology and Laboratory Medicine, Emory University, 1364 Clifton Road, Suite H175, Atlanta, GA, 30322, USA

    Xiaoxian Li

Authors
  1. Cletus A. Arciero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Limin Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kevin C. Ward
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ruth O’Regan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aysegul A. Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaoxian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception and design by XL and CAA; analysis and interpretation of data by all the authors; and drafting and reviewing of the manuscript by all the authors. XL is responsible for the overall content.

Corresponding author

Correspondence to Xiaoxian Li.

Ethics declarations

Conflicts of interest

The authors have no financial disclosures or conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arciero, C.A., Yang, J., Peng, L. et al. African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages. Breast Cancer Res Treat 166, 743–755 (2017). https://doi.org/10.1007/s10549-017-4484-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4484-1

Keywords

Search

Navigation